Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences (RNA) has granted equity awards to 22 new non-executive employees under its 2022 Employment Inducement Incentive Award Plan. The awards, approved on February 20, 2025, include non-qualified stock options to purchase 107,000 shares and 53,500 restricted stock units (RSUs).
The stock options have an exercise price of $32.53 per share, matching Avidity's closing price on Nasdaq on February 20, 2025. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest in four equal annual installments. Both awards require continued employment with Avidity and were granted as employment inducements under Nasdaq Rule 5635(c)(4).
Avidity Biosciences (RNA) ha concesso premi azionari a 22 nuovi dipendenti non esecutivi nell'ambito del suo Piano di Incentivazione all'Occupazione 2022. I premi, approvati il 20 febbraio 2025, includono opzioni su azioni non qualificate per l'acquisto di 107.000 azioni e 53.500 unità azionarie vincolate (RSU).
Le opzioni su azioni hanno un prezzo di esercizio di $32,53 per azione, corrispondente al prezzo di chiusura di Avidity su Nasdaq del 20 febbraio 2025. Le opzioni matureranno in quattro anni, con il 25% che matura dopo un anno e il resto che matura mensilmente per 36 mesi. Le RSU matureranno in quattro rate annuali uguali. Entrambi i premi richiedono la continuazione dell'impiego con Avidity e sono stati concessi come incentivi all'occupazione ai sensi della Regola 5635(c)(4) di Nasdaq.
Avidity Biosciences (RNA) ha otorgado premios de acciones a 22 nuevos empleados no ejecutivos bajo su Plan de Incentivos de Empleo 2022. Los premios, aprobados el 20 de febrero de 2025, incluyen opciones de acciones no calificadas para comprar 107,000 acciones y 53,500 unidades de acciones restringidas (RSUs).
Las opciones de acciones tienen un precio de ejercicio de $32.53 por acción, igualando el precio de cierre de Avidity en Nasdaq del 20 de febrero de 2025. Las opciones se consolidarán durante cuatro años, con el 25% consolidándose después de un año y el resto consolidándose mensualmente durante 36 meses. Las RSUs se consolidarán en cuatro cuotas anuales iguales. Ambos premios requieren empleo continuo con Avidity y se otorgaron como incentivos de empleo bajo la Regla 5635(c)(4) de Nasdaq.
Avidity Biosciences (RNA)는 2022년 고용 유인 인센티브 상여 계획에 따라 22명의 신규 비임원 직원에게 주식 보상을 부여했습니다. 이 상여는 2025년 2월 20일에 승인되었으며, 107,000주의 비자격 주식 옵션과 53,500개의 제한 주식 단위(RSU)를 포함합니다.
주식 옵션의 행사 가격은 $32.53 per 주로, 2025년 2월 20일 Avidity의 나스닥 종가와 일치합니다. 옵션은 4년에 걸쳐 분할되어, 1년 후 25%가 분할되고 나머지는 36개월 동안 매달 분할됩니다. RSU는 4개의 동등한 연간 할부로 분할됩니다. 두 상여 모두 Avidity와의 지속적인 고용을 요구하며, 나스닥 규정 5635(c)(4)에 따라 고용 유인으로 부여되었습니다.
Avidity Biosciences (RNA) a accordé des primes d'actions à 22 nouveaux employés non exécutifs dans le cadre de son Plan d'Incentive à l'Emploi 2022. Les primes, approuvées le 20 février 2025, comprennent des options d'achat d'actions non qualifiées pour l'achat de 107 000 actions et 53 500 unités d'actions restreintes (RSUs).
Les options d'actions ont un prix d'exercice de $32,53 par action, correspondant au prix de clôture d'Avidity sur le Nasdaq le 20 février 2025. Les options seront acquises sur quatre ans, avec 25 % acquises après un an et le reste acquis mensuellement sur 36 mois. Les RSUs seront acquises en quatre versements annuels égaux. Les deux primes nécessitent une poursuite de l'emploi avec Avidity et ont été accordées comme incitations à l'emploi selon la règle 5635(c)(4) du Nasdaq.
Avidity Biosciences (RNA) hat 22 neuen nicht-executive Mitarbeitern im Rahmen seines 2022 Employment Inducement Incentive Award Plans Aktienoptionen gewährt. Die Auszeichnungen, die am 20. Februar 2025 genehmigt wurden, umfassen nicht qualifizierte Aktienoptionen zum Kauf von 107.000 Aktien und 53.500 eingeschränkten Aktieneinheiten (RSUs).
Die Aktienoptionen haben einen Ausübungspreis von $32,53 pro Aktie, was dem Schlusskurs von Avidity an der Nasdaq am 20. Februar 2025 entspricht. Die Optionen werden über vier Jahre fällig, wobei 25% nach einem Jahr und der Rest monatlich über 36 Monate fällig wird. Die RSUs werden in vier gleichen jährlichen Raten fällig. Beide Auszeichnungen erfordern eine fortgesetzte Beschäftigung bei Avidity und wurden als Beschäftigungsanreize gemäß Nasdaq-Regel 5635(c)(4) gewährt.
- Successful recruitment of 22 new employees indicating company growth
- Stock price at $32.53 shows market confidence
- Potential dilution of existing shareholders due to new equity issuance
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Avidity, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Avidity, pursuant to Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare neuromuscular diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in
Investor Contact:
Kat Lange
(619) 837-5014
investors@aviditybio.com
Media Contact:
(619) 837-5016
media@aviditybio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302381975.html
SOURCE Avidity Biosciences, Inc.
FAQ
How many shares were granted in Avidity Biosciences (RNA) February 2025 inducement awards?
What is the exercise price for RNA's February 2025 stock option grants?
What is the vesting schedule for RNA's February 2025 inducement stock options?
How do the RSUs vest in RNA's February 2025 inducement grants?
